Phase Ib shows pembrolizumab elicits complete or partial remission in Hodgkin lymphoma

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Craig Moskowitz (Memorial Sloan Kettering Cancer Center, New York, NY) discusses the preliminary results of a phase Ib study evaluating the PD-1 inhibitor, pembrolizumab, in patients with classical Hodgkin lymphoma after brentuximab vedotin failure.

Year of Production:
Running Time:
Color/Sound:

2014
05:53
Color/Sound

Comments are closed.